BRIEF published on 06/07/2024 at 17:50, 2 years 3 months ago Changes in Shareholder Voting Rights at Median Technologies Share Capital Voting Rights French Regulations Median Technologies Non-voting Shares
BRIEF published on 06/07/2024 at 17:50, 2 years 3 months ago Modifications des droits de vote des actionnaires chez Median Technologies Droit De Vote Partage Le Capital Technologies Médianes Actions Sans Droit De Vote Réglementation Française
PRESS RELEASE published on 06/07/2024 at 17:45, 2 years 3 months ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and share capital as of May 31, 2024, in compliance with French regulations. The company specializes in AI-driven solutions for cancer diagnosis and treatment Share Capital Voting Rights AI Solutions Median Technologies Cancer Diagnosis
PRESS RELEASE published on 06/07/2024 at 17:45, 2 years 3 months ago Modification des droits attachés aux catégories d'actions Déclaration du nombre de droits de vote et d'actions de Median Technologies au 31 mai 2024. Découvrez les chiffres clés de l'entreprise et ses activités dans l'imagerie médicale et l'IA Euronext Growth Imagerie Médicale Intelligence Artificielle Oncologie Median Technologies
BRIEF published on 05/29/2024 at 17:50, 2 years 3 months ago Median Technologies to Attend 2024 ASCO Annual Meeting in Chicago Clinical Trials Oncology Imaging Solutions Median Technologies ASCO Annual Meeting
BRIEF published on 05/29/2024 at 17:50, 2 years 3 months ago Median Technologies participera à la réunion annuelle de l'ASCO 2024 à Chicago Solutions D'imagerie Essais Cliniques Oncologie Technologies Médianes Réunion Annuelle De L'ASCO
PRESS RELEASE published on 05/29/2024 at 17:45, 2 years 3 months ago Inside Information / Other news releases Median Technologies to participate in the 2024 ASCO Annual Meeting at McCormick Place, Chicago, IL, USA. Abstract on double reading performance in lung clinical trials. Event details and company overview Clinical Trials Oncology Medical Imaging Median Technologies ASCO Annual Meeting
BRIEF published on 05/21/2024 at 17:50, 2 years 3 months ago Median Technologies renforce sa position auprès des géants pharmaceutiques Imagerie Médicale Intelligence Artificielle Essais Cliniques Oncologie Median Technologies
BRIEF published on 05/21/2024 at 17:50, 2 years 3 months ago Median Technologies strengthens its position with pharmaceutical giants Artificial Intelligence Oncology Medical Imaging Median Technologies Clinical Tests
PRESS RELEASE published on 05/21/2024 at 17:45, 2 years 3 months ago Informations privilégiées / Autres communiqués Median Technologies devient fournisseur privilégié d'un nouveau laboratoire pharmaceutique du Top 3 mondial, renforçant ainsi sa position de leader en services d'imagerie pour les essais cliniques en oncologie Oncologie Median Technologies Laboratoire Pharmaceutique Services D'imagerie Accord-cadre De Services
Published on 09/12/2026 at 02:35, 1 day 4 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 8 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 9 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 14 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 13 hours 16 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 23 hours 36 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 8 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 8 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 11 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 days ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 2 days 11 hours ago Availability of the 2026 Interim Financial Report
